Diabetes Care, Vol 20, Issue 8 1231-1236, Copyright © 1997 by American Diabetes Association

ARTICLES

Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM

TY Saleh and PE Cryer
Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

OBJECTIVE: To test the hypothesis that because of sustained glycemic actions, bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack, we studied 15 patients with IDDM. RESEARCH DESIGN AND METHODS: On each of four occasions, the same individualized dose of NPH insulin (0.1-0.2 U/kg) was administered with either no treatment (control) or, in random sequence, oral treatment with a snack (240 ml of 2% milk plus one slice of toast, approximately 200 kcal), alanine (40 g, plus 10 g of glucose, approximately 200 kcal), or terbutaline (5.0 mg) at 2200. RESULTS: During the first half of the night (2315-0300), mean plasma glucose concentrations were higher after the snack (P < 0.02), alanine plus glucose (P < 0.01), or terbutaline (P < 0.001), compared with no treatment. During the second half of the night, mean plasma glucose levels were no different from control values (73 +/- 5 mg/dl, 4.1 +/- 0.3 mmol/l) after the snack (73 +/- 7 mg/dl, 4.1 +/- 0.4 mmol/l), tended to be higher after alanine plus glucose (96 +/- 16 mg/dl, 5.3 +/- 0.9 mmol/l), and were significantly higher after terbutaline (124 +/- 15 mg/dl, 6.9 +/- 0.8 mmol/l, P < 0.01). Nocturnal plasma glucose levels of 40 mg/dl (2.2 mmol/l) or less (which were treated with intravenous glucose) occurred on 13 occasions in seven patients in the control arm and 10 occasions in six patients in the snack arm (not significantly different from the control arm), but on only 1 occasion in the alanine-plus-glucose arm (P < 0.02) and the terbutaline arm (P < 0.02). CONCLUSIONS: In patients with IDDM given an evening dose of NPH insulin, a conventional bedtime snack exerts an inconsistent glycemic effect only during the first half of the night, and bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. R. Heller Minimizing Hypoglycemia While Maintaining Glycemic Control in Diabetes Diabetes, December 1, 2008; 57(12): 3177 - 3183. [Full Text] [PDF]

				B. E. De Galan, P. De Mol, L. Wennekes, B. J. J. Schouwenberg, and P. Smits Preserved Sensitivity to {beta}2-Adrenergic Receptor Agonists in Patients with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2878 - 2881. [Abstract] [Full Text] [PDF]

				B. Raju, A. M. Arbelaez, S. M. Breckenridge, and P. E. Cryer Nocturnal Hypoglycemia in Type 1 Diabetes: An Assessment of Preventive Bedtime Treatments J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2087 - 2092. [Abstract] [Full Text] [PDF]

				P. E. Cryer Diverse Causes of Hypoglycemia-Associated Autonomic Failure in Diabetes N. Engl. J. Med., May 27, 2004; 350(22): 2272 - 2279. [Full Text] [PDF]

				P. E. Cryer, S. N. Davis, and H. Shamoon Hypoglycemia in Diabetes Diabetes Care, June 1, 2003; 26(6): 1902 - 1912. [Abstract] [Full Text] [PDF]

				N P Wright and J K H Wales The incidence of hypoglycaemia in children with type 1 diabetes and treated asthma Arch. Dis. Child., February 1, 2003; 88(2): 155 - 156. [Abstract] [Full Text] [PDF]

				P. E. Cryer and B. P. Childs Negotiating the Barrier of Hypoglycemia in Diabetes Diabetes Spectr, January 1, 2002; 15(1): 20 - 27. [Abstract] [Full Text] [PDF]